Shares in Value Logo
Product Review Img Vertical

Date : 25/02/2021

Little Green Pharma’s (ASX:LGP) performance in First-Half of FY21?

Cannabis is a hot industry at the moment and it is demanding the attention of a lot of investors. Some of the top cannabis stocks on the ASX have performed remarkably during 2020 on the back of innovative product candidates. The cannabis market is estimated to grow by over 30% into a $40 billion market by 2023. Much of this will be led by the USA and Canada. During September 2020, the TGA down-scheduled cannabidiol (CBD). This allows Australian patients to purchase CBD products from a pharmacist over the counter.

Little Green Pharma Ltd. is a Perth headquartered cannabis company that produces medicinal cannabis products for sale to Australian patients. Its medicines are cultivated, without pesticides, in a hydroponic facility. The company has growth tremendously in 2021 with the stock performance coming in at 21% in the year-to-date chart.

During the first half of FY21, the company exported the first shipment of its medicinal cannabis oils to Germany. Little Green Pharma obtained a GMP manufacturing license from the TGA for its South West WA manufacturing facility. Both – number of customers and sales volumes have grown in the first half of FY2021.

Most recently Little Green Pharma announced that it will exclusively supply medicinal cannabis oil products to the enrolled patients and cover study costs of the medical cannabis quality-of-life study to be conducted by the University of Sydney. The study aims to investigate the quality of life and health economics on patients who have been prescribed medicinal cannabis for chronic diseases, the Australian pharmaceutical company said Thursday.The study is expected to be conducted over a two-year period and plans to recruit a minimum of 2,100 patients by June 30, according to the release.

After raising $17 million via a share placement earlier this month, Little Green Pharma has also bolstered its balance sheet and aligned itself to continue pushing for growth.

Looking for Growth Stocks?

Growth stocks are potentially one of the hardest to pick as there are a lot of factors that need to be considered – from industry tailwinds to financial health of the individual stocks, and a lot of little things in between them. Shares in Value research team have picked their top 3 ASX stocks to buy in 2021. Click here to download the report for free.

 

Are You Looking To Buy The Best Stocks In 2022?

Stay on top of upcoming market trends! Whether you are an SMSF investor or a young investor with your portfolio, we cover a wide range of stocks across all sectors, including mining, financials, industrials, real estate, technology, health and biotech, etc. It will give you an edge to invest and trade ASX listed stocks across large, mid and small caps with an advantage.

Get stock tips with our Market Experts. We help self-directed investors and self-managed super funds (SMSF) make smarter investment decisions and get better returns. Fill in your details and download your free Report instantly for Top 3 Dividend Stocks to buy in 2022!

 

Top 5 ASX Stocks
to Buy for Capital Growth in 2022

asx landing page
The hardest part to finding growth stocks is having an ability to understand the finer details of these companies from their valuations through to first mover advantage and having key factors on hand to make informed investment decisions.

Our experts take the guesswork out.

Download Your Free Report

By downloading this report you agree to the TERMS AND CONDITIONS and our PRIVACY POLICY

Scroll to Top

Login

By submitting this form, I agree to the TERMS AND CONDITIONS and PRIVATE POLICY

Please fill in your details to download the free dividend shares report.

We will send your report instantly. Please put your correct email address and phone number.